# Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy

> **NIH NIH R43** · LUMINARY THERAPEUTICS, INC. · 2021 · $399,658

## Abstract

Abstract
The use of T cells engineered to express specific chimeric antigen receptors (CARs) to treat cancer has
generated durable cures for many types of cancer and resulted in the first FDA approved CAR-T cell therapy to
treat childhood acute lymphoblastic leukemia in 2017. Despite this success, CAR-T immunotherapies have been
much less effective at targeting solid tumors. Part of this limited success stems from the solid tumor
microenvironment, which forms a physical barrier to immune cell infiltration and produces soluble factors that
downregulate T cell activity and accelerate T cell exhaustion. While immunotherapies targeting solid tumors are
initially effective, the tumor microenvironment’s inhibition of T cells prevents these treatments from producing
durable responses. In this application, we propose a novel CAR-T cell therapy aimed to improve outcomes for
patients with advanced stage pancreatic cancer by overcoming the deficiencies that plague current CAR-T cell
therapies. To this end, we will engineer T cells to express multiple CARs, enabling these cells to target tumor
cells and cells in the immune-suppressive tumor microenvironment. Specifically, we will leverage the non-viral,
Tc Buster DNA transposon system to insert a large multicistronic genetic construct containing multiple CARs
and a selection marker into T cells. Using this platform, we will generate T cells with CARs targeting mesothelin
(MSLN), a protein expressed by 80-85% of pancreatic cancer tumors, and fibroblast activation protein (FAP), a
marker of cancer associated fibroblasts in the tumor microenvironment. We will then select a pure population of
T cells expressing MSLN- and FAP-CARs and determine the activity and specificity of these cells in vitro. We
expect that engineered T cells will generate a specific and robust response, eliciting cytotoxic functions only
against cells expressing their target antigen. We will then determine the efficacy of engineered T cells in vivo
using a xenograft mouse model to generate MSLN and FAP positive pancreatic carcinomas followed by adoptive
transfer of T cells. We expect immunotherapeutic delivery of bispecific T cells expressing FAP-CARs and MSLN-
CARs will elicit a robust and long-lasting T cell response against MSLN+/FAP+ solid tumors resulting in tumor
shrinkage and increased survival. Furthermore, we expect the development of a flexible, efficient, and reliable
process to generate bispecific T cells with a single, non-viral gene delivery approach will facilitate the emergence
of novel therapies to overcome many issues facing engineered T cell therapy today, including antigen escape
and target specificity.

## Key facts

- **NIH application ID:** 10156815
- **Project number:** 1R43CA254820-01A1
- **Recipient organization:** LUMINARY THERAPEUTICS, INC.
- **Principal Investigator:** Nicole J. Shirkey-Son
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $399,658
- **Award type:** 1
- **Project period:** 2021-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10156815

## Citation

> US National Institutes of Health, RePORTER application 10156815, Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy (1R43CA254820-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10156815. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*